PT3206692T - Tratamento da doença hepática gordurosa utilizando antagonistas dos recetores de glicocorticoides e mineralocorticoides - Google Patents

Tratamento da doença hepática gordurosa utilizando antagonistas dos recetores de glicocorticoides e mineralocorticoides

Info

Publication number
PT3206692T
PT3206692T PT158512384T PT15851238T PT3206692T PT 3206692 T PT3206692 T PT 3206692T PT 158512384 T PT158512384 T PT 158512384T PT 15851238 T PT15851238 T PT 15851238T PT 3206692 T PT3206692 T PT 3206692T
Authority
PT
Portugal
Prior art keywords
glucocorticoid
receptor antagonists
liver disease
fatty liver
disease treatment
Prior art date
Application number
PT158512384T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of PT3206692T publication Critical patent/PT3206692T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT158512384T 2014-10-15 2015-10-14 Tratamento da doença hepática gordurosa utilizando antagonistas dos recetores de glicocorticoides e mineralocorticoides PT3206692T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15

Publications (1)

Publication Number Publication Date
PT3206692T true PT3206692T (pt) 2024-04-30

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158512384T PT3206692T (pt) 2014-10-15 2015-10-14 Tratamento da doença hepática gordurosa utilizando antagonistas dos recetores de glicocorticoides e mineralocorticoides

Country Status (22)

Country Link
US (5) US10238659B2 (enExample)
EP (2) EP4353310A3 (enExample)
JP (1) JP6761410B2 (enExample)
KR (1) KR102435956B1 (enExample)
CN (2) CN111557942B (enExample)
AU (1) AU2015333645B2 (enExample)
BR (1) BR112017007860B1 (enExample)
CA (1) CA2964625C (enExample)
DK (1) DK3206692T3 (enExample)
ES (1) ES2978871T3 (enExample)
FI (1) FI3206692T3 (enExample)
IL (1) IL251729B (enExample)
MX (1) MX2017004943A (enExample)
NZ (1) NZ731060A (enExample)
PH (1) PH12017500710B1 (enExample)
PL (1) PL3206692T3 (enExample)
PT (1) PT3206692T (enExample)
RU (1) RU2718921C2 (enExample)
SG (1) SG11201703024VA (enExample)
UA (1) UA123537C2 (enExample)
WO (1) WO2016061195A1 (enExample)
ZA (1) ZA201702813B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102435956B1 (ko) 2014-10-15 2022-08-23 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 및 미네랄로코르티코이드 수용체 길항제를 사용한 지방간 질환 치료법
CA3102099C (en) * 2018-06-04 2023-09-26 Corcept Therapeutics Incorporated Pyrimidine cyclohexenyl glucocorticoid receptor modulators
EP3941460B1 (en) 2019-03-18 2025-10-15 Nieman, Lynnette K. Mifepristone for use in improving insulin sensitivity
WO2021226260A1 (en) * 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
IL297840A (en) * 2020-05-06 2023-01-01 Corcept Therapeutics Inc Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
CN116848092A (zh) * 2020-12-21 2023-10-03 科赛普特治疗公司 制备嘧啶环己基糖皮质激素受体调节剂的方法
EP4333848A4 (en) * 2021-05-05 2025-03-19 Corcept Therapeutics Incorporated Methods for reducing liver fat and treating fatty liver disease
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7745657B2 (en) 2005-05-18 2010-06-29 Merck Sharp & Dohme Corp. D-homoandrosta-17-yl carbamate derivatives as selective glucocorticoid receptor ligands
US8389472B2 (en) 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
EP1941040A1 (en) * 2005-09-19 2008-07-09 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EP2158203A2 (en) * 2007-04-13 2010-03-03 Schering Corporation Pyrimidinedione derivatives and use thereof
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
PH12013501906A1 (en) * 2011-03-18 2013-12-16 Corcept Therapeutics Inc Pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102435956B1 (ko) 2014-10-15 2022-08-23 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 및 미네랄로코르티코이드 수용체 길항제를 사용한 지방간 질환 치료법

Also Published As

Publication number Publication date
RU2017114596A3 (enExample) 2019-05-08
US20190151318A1 (en) 2019-05-23
EP3206692A1 (en) 2017-08-23
IL251729B (en) 2020-03-31
JP2017531013A (ja) 2017-10-19
CA2964625C (en) 2023-03-07
AU2015333645A1 (en) 2017-05-04
RU2017114596A (ru) 2018-11-15
EP3206692B1 (en) 2024-04-03
PH12017500710B1 (en) 2024-01-17
MX2017004943A (es) 2017-07-19
CN107106562A (zh) 2017-08-29
WO2016061195A1 (en) 2016-04-21
CN111557942B (zh) 2023-10-03
EP4353310A3 (en) 2024-06-19
EP3206692A4 (en) 2018-05-30
US10238659B2 (en) 2019-03-26
SG11201703024VA (en) 2017-05-30
NZ731060A (en) 2023-07-28
ES2978871T3 (es) 2024-09-23
CN107106562B (zh) 2020-08-18
FI3206692T3 (fi) 2024-05-06
EP4353310A2 (en) 2024-04-17
RU2718921C2 (ru) 2020-04-15
BR112017007860B1 (pt) 2023-03-07
BR112017007860A2 (pt) 2018-01-16
US20160106749A1 (en) 2016-04-21
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
DK3206692T3 (da) 2024-04-29
CA2964625A1 (en) 2016-04-21
PL3206692T3 (pl) 2024-07-22
KR102435956B1 (ko) 2022-08-23
AU2015333645B2 (en) 2020-01-30
UA123537C2 (uk) 2021-04-21
IL251729A0 (en) 2017-06-29
JP6761410B2 (ja) 2020-09-23
PH12017500710A1 (en) 2017-10-09
US20210085682A1 (en) 2021-03-25
KR20170066646A (ko) 2017-06-14
US11590135B2 (en) 2023-02-28
ZA201702813B (en) 2019-05-29
US12226417B2 (en) 2025-02-18
US20230218621A1 (en) 2023-07-13
CN111557942A (zh) 2020-08-21

Similar Documents

Publication Publication Date Title
ZA201702813B (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
SG11201609645YA (en) Device for connecting the structural elements of ribs and reticular structures
IL247713A0 (en) Indazole 3-carboxyamides converted at the 5-position, their preparation and their use
AU201710083S (en) Bowl and Covered Bowl
GB201404470D0 (en) Therapeutic methods and materials
AU357565S (en) Mixing bowls
SG11201608217PA (en) Fatty acid composition and use thereof
IL246779A0 (en) Methods for the treatment and prevention of kidney disorders and fatty liver disorders
ZA201706671B (en) Process for the preparation of androgen receptor antagonists and intermediates thereof
IL249203A0 (en) Androgen receptor modulators and methods of using them
GB2530559B (en) Mixing bowl
IL265560A (en) Preparations containing a mineralocorticoid receptor antagonist and their uses
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
IL247828A0 (en) Progesterone compounds
IL246944A0 (en) A process for the preparation of abiraterone acetate and its intermediates
GB201612052D0 (en) Animal claw shearing apparatuses and methods of using the same
GB2544560B (en) Mixing bowl
GB201810451D0 (en) Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
GB201411741D0 (en) Mixing bowl stand
GB201419977D0 (en) Dynamic mixer and mixing
GB201402629D0 (en) Improved mixer and associated methods